COVID-19 occurrence and symptoms depending on vaccination status: a retrospective single-centre analysis of 27,209 patients
Abstract
Introduction: Widespread immunization is critical to bringing the COVID-19 pandemic to an end. The objective of this cross-sectional data analysis was to investigate the impact of vaccination on the frequency of COVID-19 occurrence and the presence of its symptoms and clinical presentations.
Material and methods: This was a retrospective, cross-sectional study, analysing medical records of patients hospitalized at the Dr Antoni Jurasz University Hospital No. 1 in Bydgoszcz in the years 2019–2021. The analysis considered age, sex, vaccination status, the result of the reverse transcription polymerase chain reaction (RT-PCR) test for the detection of SARS-CoV-2 RNA, and disease symptoms and clinical presentations in accordance with ICD-10 codes.
Results: The study group consisted of 27,209 patients. There were 1,393 persons (5.12%) who tested positive for COVID-19. The vaccinated patients accounted for 17.3% (n = 4,704). Those vaccinated were significantly less likely to test positive for COVID-19 (3.93% vs. 5.38%; p < 0.0001). Among unvaccinated patients with a positive test result for COVID-19, symptoms and/or clinical presentations occurred in 359 study participants (29.72%), while in vaccinated COVID-19-positive patients only in 49 persons (26.49%). The symptoms that occurred in both vaccinated and unvaccinated patients were mainly respiratory and circulatory. The most common clinical presentation, both in the group of vaccinated and unvaccinated patients, was viral pneumonia, not elsewhere classified (J12), which occurred in 17.30% and 9.19% of patients, respectively (p = 0.005). Other symptoms and clinical presentations showing a statistically significant difference in the frequency of occurrence between the groups were pneumonia in diseases classified elsewhere (J17; p = 0.019) and abnormalities of breathing (R06; p = 0.001).
Conclusions: Vaccination against COVID-19 protects against symptomatic disease.
Keywords: SARS-CoV-2COVID-19vaccinationsymptoms
References
- WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ (12.07.2023).
- Patel R, Kaki M, Potluri VS, et al. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022; 18(1): 2002083.
- WHO COVID19 Vaccine Tracker. https://covid19.trackvaccines.org/vaccines/approved/ (12.07.2023).
- Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022; 26(5): 1770–1776.
- Narodowy Instytut Zdrowia Publicznego Państwowy Zakład Higieny – Państwowy Instytut Badawczy. Gdzie można znaleźć informacje na temat skuteczności klinicznej szczepionek przeciw COVID-19? https://szczepienia.pzh.gov.pl/faq/gdzie-mozna-znalezc-informacje-na-temat-skutecznosci-klinicznej-szczepionek-przeciw-covid-19/ (12.07.2023).
- Rogaczewski P, Cyls D, Kasprzak M, et al. The impact of the COVID-19 pandemic on hospital functioning and mortality among non-COVID-19 patients. Med Res J. 2022; 7(4): 314–320.
- Lackowski P, Piasecki M, Kasprzak M, et al. COVID-19 pandemic year in the cardiology department. Med Res J. 2021; 6(1): 40–46.
- Grzelakowska K, Kryś J. The impact of COVID-19 on healthcare workers’ absenteeism: infections, quarantines, sick leave — a database analysis of the Antoni Jurasz University Hospital No. 1. in Bydgoszcz, Poland. Med Res J. 2021; 6(1): 47–52.
- Kubica J, Ostrowska M, Stolarek W, et al. Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study). ESC Heart Fail. 2022; 9(1): 721–728.
- Fiolet T, Kherabi Y, MacDonald CJ, et al. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022; 28(2): 202–221.
- Chen P, Shi X, He W, et al. mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Hum Vaccin Immunother. 2022; 18(1): 2040330.
- Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287): 1819–1829.
- Tande AJ, Pollock BD, Shah ND, et al. Impact of the coronavirus disease 2019 (COVID-19) vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening. Clin Infect Dis. 2022; 74(1): 59–65.
- Khoury J, Najjar-Debbiny R, Hanna A, et al. COVID-19 vaccine – long term immune decline and breakthrough infections. Vaccine. 2021; 39(48): 6984–6989.
- Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373: n1088.
- Ahmad Malik J, Ahmed S, Shinde M, et al. The impact of COVID-19 on comorbidities: a review of recent updates for combating it. Saudi J Biol Sci. 2022; 29(5): 3586–3599.
- Bigdelou B, Sepand MR, Najafikhoshnoo S, et al. COVID-19 and preexisting comorbidities: risks, synergies, and clinical outcomes. Front Immunol. 2022; 13: 890517.
- Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020; 96(1142): 753–758.
- Azevedo RB, Botelho BG, Hollanda JV, et al. Covid-19 and the cardiovascular system: a comprehensive review. J Hum Hypertens. 2021; 35(1): 4–11.
- Bloomberg. More Than 12.7 Billion Shots Given: Covid-19 Tracker. https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/ (12.07.2023).
- Serwis Rzeczypospolitej Polskiej. Raport szczepień przeciwko COVID-19. https://www.gov.pl/web/szczepimysie/raport-szczepien-przeciwko-covid-19 (12.07.2023).
- Food and Drug Administration News Release. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age (12.07.2023).